pimobendan has been researched along with vesnarinone in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Erhardt, PW | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Asanoi, H; Inoue, H | 1 |
| Furukawa, Y; Iwasaki, A; Matsumori, A; Nakamura, T; Okada, I; Ono, K; Sasayama, S; Shioi, T | 1 |
| Matsumori, A; Nose, Y; Ono, K; Sasayama, S; Sato, Y; Shioi, T | 1 |
| Sasayama, S | 3 |
| Matsumori, A; Nunokawa, Y; Sasayama, S | 1 |
3 review(s) available for pimobendan and vesnarinone
| Article | Year |
|---|---|
In search of the digitalis replacement.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiotonic Agents; Cyclic AMP; Digitalis Glycosides; Heart Failure; Humans; Myocardial Contraction; Receptors, Adrenergic, beta; Structure-Activity Relationship | 1987 |
Inotropic agents in the treatment of heart failure: despair or hope?
Topics: Adrenergic beta-Agonists; Cardiotonic Agents; Cyclic AMP; Digitalis; Heart Failure; Humans; Plants, Medicinal; Plants, Toxic; Prognosis; Pyrazines; Pyridazines; Quinolines | 1997 |
[Inotropic agents].
Topics: Adrenergic alpha-Agonists; Animals; Cardiotonic Agents; Clinical Trials as Topic; Digitalis Glycosides; Heart Failure; Humans; Pyrazines; Pyridazines; Quinolines | 2003 |
6 other study(ies) available for pimobendan and vesnarinone
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Positive inotropic agents: a double-edged sword for chronic heart failure.
Topics: Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Heart Failure; Humans; Pyrazines; Pyridazines; Quinolines | 1996 |
Inotropic agents differentially inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Amrinone; Animals; Cardiotonic Agents; Cell Line; Culture Media; Lipopolysaccharides; Macrophages; Mice; Nitric Oxide Synthase; Nitrites; Phosphodiesterase Inhibitors; Pyrazines; Pyridazines; Quinolines | 1996 |
Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; 8-Bromo Cyclic Adenosine Monophosphate; Amrinone; Cells, Cultured; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Heart Failure; Humans; Interleukin-1; Interleukin-6; Kinetics; Leukocytes, Mononuclear; Lipopolysaccharides; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperidines; Pyrazines; Pyridazines; Quinazolines; Quinolines; Tumor Necrosis Factor-alpha | 1996 |
Pimobendan inhibits the activation of transcription factor NF-kappaB: a mechanism which explains its inhibition of cytokine production and inducible nitric oxide synthase.
Topics: Amrinone; Animals; Cardiotonic Agents; Colforsin; Cytokines; Humans; Interleukin-1; Luciferases; Macrophages; Mice; NF-kappa B; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Phosphodiesterase Inhibitors; Pyrazines; Pyridazines; Quinolines; Tetradecanoylphorbol Acetate; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2000 |
Inotropic agents and immune modulation.
Topics: Adjuvants, Immunologic; Animals; Cardiotonic Agents; Clinical Trials as Topic; Cytokines; Heart Failure; Humans; Myocardium; Phosphodiesterase Inhibitors; Pyrazines; Pyridazines; Quality of Life; Quinolines; Time Factors | 2002 |